Ionis and Roche to develop RNAi AMD drug in $760m dealIonis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug Share XIonis and Roche to develop RNAi AMD drug in $760m dealhttps://pharmaphorum.com/news/ionis-and-roche-to-develop-rnai-amd-drug-in-760m-deal/
Celltrion/Teva Rituxan biosimilar edges closer to US approvalIt looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in Share XCelltrion/Teva Rituxan biosimilar edges closer to US approvalhttps://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/
Roche unveils long-term data from MS blockbuster OcrevusPeople with relapsing multiple sclerosis treated sooner with Roche’s Ocrevus saw a faster reduction in disease activity and Share XRoche unveils long-term data from MS blockbuster Ocrevushttps://pharmaphorum.com/news/roche-unveils-long-term-data-from-ms-blockbuster-ocrevus/
Celltrion’s Rituxan biosimilar gets glowing review ahead of key meetingReviewers from the FDA have given Celltrion’s biosimilar of Roche’s blood cancer blockbuster Rituxan a glowing report ahead Share XCelltrion’s Rituxan biosimilar gets glowing review ahead of key meetinghttps://pharmaphorum.com/news/celltrions-rituxan-biosimilar-gets-glowing-review-ahead-of-key-meeting/
Roche’s Hemlibra approved in expanded haemophilia A useRoche’s Hemlibra has been approved in an expanded use in haemophilia A in the US, as the Swiss Share XRoche’s Hemlibra approved in expanded haemophilia A usehttps://pharmaphorum.com/news/roches-hemlibra-approved-in-expanded-haemophilia-a-use/
Trial shows Roche’s new flu drug helps reduce symptoms in at-risk patientsBaloxavir marboxil, a flu drug seen by Roche as a successor to Tamiflu, significantly sped time to relief Share XTrial shows Roche’s new flu drug helps reduce symptoms in at-risk patientshttps://pharmaphorum.com/news/trial-shows-roches-new-flu-drug-helps-reduce-symptoms-in-at-risk-patients/
Roche aims to extend shelf life of Xolair with new prefilled pen formulationThe FDA has approved a new prefilled syringe formulation for Roche’s asthma drug Xolair, as the Swiss company Share XRoche aims to extend shelf life of Xolair with new prefilled pen formulationhttps://pharmaphorum.com/news/roche-aims-to-extend-shelf-life-of-xolair-with-new-prefilled-pen-formulation/
Roche buys Tusk, plus cancer immunotherapy drug, for £62mRoche has bought immuno-oncology biotech firm Tusk Therapeutics for an upfront payment of £62 million. Tusk’s shareholders will Share XRoche buys Tusk, plus cancer immunotherapy drug, for £62mhttps://pharmaphorum.com/news/roche-buys-tusk-plus-cancer-immunotherapy-drug-for-62m/
Roche Diabetes Care partners with digital therapeutics firm IesoRoche’s diabetes arm is working with Ieso Digital Health to test the Cambridge, UK-based digital therapeutics firm’s mental Share XRoche Diabetes Care partners with digital therapeutics firm Iesohttps://pharmaphorum.com/news/roche-diabetes-care-ieso-digital-health/
